In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cells.

Recent experimental data showed that the PI3K pathway contributes to resistance to temozolomide (TMZ) in paediatric glioblastoma and that this effect is reversed by combination treatment of TMZ with a PI3K inhibitor. Our aim is to assess whether this combination results in metabolic changes that are...

Full description

Saved in:
Bibliographic Details
Main Authors: Nada M S Al-Saffar, Alice Agliano, Lynley V Marshall, L Elizabeth Jackson, Geetha Balarajah, Jasmin Sidhu, Paul A Clarke, Chris Jones, Paul Workman, Andrew D J Pearson, Martin O Leach
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-01-01
Series:PLoS ONE
Online Access:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0180263&type=printable
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850133863464960000
author Nada M S Al-Saffar
Alice Agliano
Lynley V Marshall
L Elizabeth Jackson
Geetha Balarajah
Jasmin Sidhu
Paul A Clarke
Chris Jones
Paul Workman
Andrew D J Pearson
Martin O Leach
author_facet Nada M S Al-Saffar
Alice Agliano
Lynley V Marshall
L Elizabeth Jackson
Geetha Balarajah
Jasmin Sidhu
Paul A Clarke
Chris Jones
Paul Workman
Andrew D J Pearson
Martin O Leach
author_sort Nada M S Al-Saffar
collection DOAJ
description Recent experimental data showed that the PI3K pathway contributes to resistance to temozolomide (TMZ) in paediatric glioblastoma and that this effect is reversed by combination treatment of TMZ with a PI3K inhibitor. Our aim is to assess whether this combination results in metabolic changes that are detectable by nuclear magnetic resonance (NMR) spectroscopy, potentially providing metabolic biomarkers for PI3K inhibition and TMZ combination treatment. Using two genetically distinct paediatric glioblastoma cell lines, SF188 and KNS42, in vitro 1H-NMR analysis following treatment with the dual pan-Class I PI3K/mTOR inhibitor PI-103 resulted in a decrease in lactate and phosphocholine (PC) levels (P<0.02) relative to control. In contrast, treatment with TMZ caused an increase in glycerolphosphocholine (GPC) levels (P≤0.05). Combination of PI-103 with TMZ showed metabolic effects of both agents including a decrease in the levels of lactate and PC (P<0.02) while an increase in GPC (P<0.05). We also report a decrease in the protein expression levels of HK2, LDHA and CHKA providing likely mechanisms for the depletion of lactate and PC, respectively. Our results show that our in vitro NMR-detected changes in lactate and choline metabolites may have potential as non-invasive biomarkers for monitoring response to combination of PI3K/mTOR inhibitors with TMZ during clinical trials in children with glioblastoma, subject to further in vivo validation.
format Article
id doaj-art-cb11a1ee5827424e87467afe500fd721
institution OA Journals
issn 1932-6203
language English
publishDate 2017-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj-art-cb11a1ee5827424e87467afe500fd7212025-08-20T02:31:51ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01127e018026310.1371/journal.pone.0180263In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cells.Nada M S Al-SaffarAlice AglianoLynley V MarshallL Elizabeth JacksonGeetha BalarajahJasmin SidhuPaul A ClarkeChris JonesPaul WorkmanAndrew D J PearsonMartin O LeachRecent experimental data showed that the PI3K pathway contributes to resistance to temozolomide (TMZ) in paediatric glioblastoma and that this effect is reversed by combination treatment of TMZ with a PI3K inhibitor. Our aim is to assess whether this combination results in metabolic changes that are detectable by nuclear magnetic resonance (NMR) spectroscopy, potentially providing metabolic biomarkers for PI3K inhibition and TMZ combination treatment. Using two genetically distinct paediatric glioblastoma cell lines, SF188 and KNS42, in vitro 1H-NMR analysis following treatment with the dual pan-Class I PI3K/mTOR inhibitor PI-103 resulted in a decrease in lactate and phosphocholine (PC) levels (P<0.02) relative to control. In contrast, treatment with TMZ caused an increase in glycerolphosphocholine (GPC) levels (P≤0.05). Combination of PI-103 with TMZ showed metabolic effects of both agents including a decrease in the levels of lactate and PC (P<0.02) while an increase in GPC (P<0.05). We also report a decrease in the protein expression levels of HK2, LDHA and CHKA providing likely mechanisms for the depletion of lactate and PC, respectively. Our results show that our in vitro NMR-detected changes in lactate and choline metabolites may have potential as non-invasive biomarkers for monitoring response to combination of PI3K/mTOR inhibitors with TMZ during clinical trials in children with glioblastoma, subject to further in vivo validation.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0180263&type=printable
spellingShingle Nada M S Al-Saffar
Alice Agliano
Lynley V Marshall
L Elizabeth Jackson
Geetha Balarajah
Jasmin Sidhu
Paul A Clarke
Chris Jones
Paul Workman
Andrew D J Pearson
Martin O Leach
In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cells.
PLoS ONE
title In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cells.
title_full In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cells.
title_fullStr In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cells.
title_full_unstemmed In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cells.
title_short In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cells.
title_sort in vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with pi3k inhibition in paediatric glioblastoma cells
url https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0180263&type=printable
work_keys_str_mv AT nadamsalsaffar invitronuclearmagneticresonancespectroscopymetabolicbiomarkersforthecombinationoftemozolomidewithpi3kinhibitioninpaediatricglioblastomacells
AT aliceagliano invitronuclearmagneticresonancespectroscopymetabolicbiomarkersforthecombinationoftemozolomidewithpi3kinhibitioninpaediatricglioblastomacells
AT lynleyvmarshall invitronuclearmagneticresonancespectroscopymetabolicbiomarkersforthecombinationoftemozolomidewithpi3kinhibitioninpaediatricglioblastomacells
AT lelizabethjackson invitronuclearmagneticresonancespectroscopymetabolicbiomarkersforthecombinationoftemozolomidewithpi3kinhibitioninpaediatricglioblastomacells
AT geethabalarajah invitronuclearmagneticresonancespectroscopymetabolicbiomarkersforthecombinationoftemozolomidewithpi3kinhibitioninpaediatricglioblastomacells
AT jasminsidhu invitronuclearmagneticresonancespectroscopymetabolicbiomarkersforthecombinationoftemozolomidewithpi3kinhibitioninpaediatricglioblastomacells
AT paulaclarke invitronuclearmagneticresonancespectroscopymetabolicbiomarkersforthecombinationoftemozolomidewithpi3kinhibitioninpaediatricglioblastomacells
AT chrisjones invitronuclearmagneticresonancespectroscopymetabolicbiomarkersforthecombinationoftemozolomidewithpi3kinhibitioninpaediatricglioblastomacells
AT paulworkman invitronuclearmagneticresonancespectroscopymetabolicbiomarkersforthecombinationoftemozolomidewithpi3kinhibitioninpaediatricglioblastomacells
AT andrewdjpearson invitronuclearmagneticresonancespectroscopymetabolicbiomarkersforthecombinationoftemozolomidewithpi3kinhibitioninpaediatricglioblastomacells
AT martinoleach invitronuclearmagneticresonancespectroscopymetabolicbiomarkersforthecombinationoftemozolomidewithpi3kinhibitioninpaediatricglioblastomacells